| 研究業績：論文 |
・Muso E, Ito-Ihara T, Ono T, Imai E, Yamagata K, Akamatsu A, Suzuki K.：Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Infect Dis. 57(5):17-8（2004）
・Tanaka M, Yamada S, Iwasaki Y, Sugishita T, Yonemoto S, Tsukamoto T, Fukui S, Takasu K, Muso E.：Impact of obesity on IgA nephropathy: comparative ultrastructural study between obese and non-obese patients. Nephron Clin Pract. 112(2):71-8 (2009)
・Muso E, Okuzaki D, Kobayashi S, Iwasaki Y, Sakurai MA, Ito A, Nojima H.：Ficolin-1 is up-regulated in leukocytes and glomeruli from microscopic polyangiitis patients.Autoimmunity. Dec;46(8):513-24 (2013)
・武曾惠理：～男女共同参画委員会より～ 学会での男女共同参画活動の展望 －日本腎臓学会からの提言－ 肝臓 vol.55 no.7 一般社団法人日本肝臓学会 pp.413-417 ( 2014.)
・Tobino K, Muso E, Iwasaki Y, Yonemoto S, Kasuno K, Tsukamoto T, Nakamura H, Tomino Y.：Gender- and disease-specific urinary thioredoxin in chronic kidney disease patients with or without type 2 diabetic nephropathy. Nephrology (Carlton). May;20(5):368-74.(2015)
・Muso E, Mune M, Hirano T, et al : A Prospective Observational Survey on the Long-Term Effect of LDL Apheresis on Drug-Resistant Nephrotic Syndrome. Nephron Extra.29;5(2):ｐｐ58-66 ,(2015 )
・武曾惠理：特集/腎臓病療養指導とチーム医療：「腎臓病療養指導とチーム医療」特集に寄せて：日本腎臓学会誌 57(5),p804-805,（2015,）
・武曾惠理、垣田浩子：総説 多彩な原因疾患による難治性ネフローゼ症候群に対するアフェレシス療法の効果－現況と今後の展望－：日本アフェレシス学会誌 37巻1号 pp24-34(2018)
・Handa T, Kakita H, Tateishi Y, Endo T, Suzuki H, Katayama T, Tsukamoto T, Muso E：The features in IgA-dominant infection-related glomerulonephritis distinct from IgA nephropathy:a single-center study：Clinical and Experimental Nephrology Published online:21 March (2018)
・武曾惠理：特集「IgA腎症―診断・治療の最新動向―」IgA腎症の治療学 7.抗血小板・抗凝固治療：日本臨牀 第77巻・第4号 pp696‐702（2019.）
・Saito T , Muso ,E et al Apolipoprotein E-related glomerular disorders :Kidney Int. Feb;97(2):279-288 2020
・Uno K., Muso E. et al. Impaired HVJ-stimulated Interferon producing capacity in MPO-ANCA-associated vasculitis with rapidly progressive glomerulonephritis lead to susceptibility to infection」Cytokine. Dec;136:155221. 2020
・Wada T., Hara A, Muso E, et al .: Effects of LDL apheresis on proteinuria in patients with diabetes mellitus, severe proteinuria, and dyslipidemia. Clin.Exp.Nephrol. 25.1-8, 2021
・Muso E, Sakai S, Ogura Y, Yukawa S, Nishizawa Y, Yorioka N, Saito T, Mune M, Sugiyama S, Iino Y, Hirano T, Hattori M, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Oda H, Mori K, Kimura H, Ito O, Nishiyama A, Maruyama S, Inagi R, Fujimoto S, Tsukamoto T, Suzuki Y, Honda H, Babazono T, Tsuruya K, Yuzawa Y. Favorable therapeutic efficacy of low-density lipoprotein apheresis for nephrotic syndrome with impaired renal function Ther Apher Dial. 2021 May 31. doi: 10.1111/1744-9987.13694. Online ahead of print/
|
